CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
Rafei H, Basar R, Acharya S, Hsu YS, Liu P, Zhang D, Bohn T, Liang Q, Mohanty V, Upadhyay R, Li P, Phadatare P, Dede M, Xiong D, Fan H, Jones CM, Kunz S, Daher M, Nunez Cortes AK, Shanley M, Liu B, Moseley SM, Zhang C, Fang D, Banerjee P, Uprety N, Li Y, Shrestha R, Wan X, Shen H, Woods V, Gilbert AL, Rawal S, Dou J, Tan Y, Park JM, Reyes Silva F, Biederstädt A, Kaplan M, Jiang XR, Biederstädt I, Kumar B, Tiberti S, Moore M, Jin J, Yang RZ, Muniz-Feliciano L, Rosemore S, Lin P, Deyter GM, Fowlkes NW, Jain AK, Marin D, Maitra A, Chen K, Bopp T, Shpall EJ, Rezvani K
Applications: WB
Reactive species: Human
"Abstract: Chimeric antigen receptor (CAR) natural killer (NK) cell immunotherapy offers a promising approach against cancer1-3. However, the molecular mechanisms that regulate CAR-NK cell activity remain unclear. Here we identify the transcription factor cyclic AMP response element modulator (CREM) as a crucial regulator of NK cell function. Transcriptomic analysis revealed a significant induction of CREM in CAR-NK cells during the peak of effector function after adoptive transfer in a tumour mouse model, and this peak coincided with signatures of both activation and dysfunction. We demonstrate that both CAR activation and interleukin-15 signalling rapidly induce CREM upregulation in NK cells. Functionally, CREM deletion enhances CAR-NK cell effector function both in vitro and in vivo and increases resistance to tumour-induced immunosuppression after rechallenge. Mechanistically, we establish that induction of CREM is mediated by the PKA-CREB signalling pathway, which can be activated by immunoreceptor tyrosine-based activation motif signalling downstream of CAR activation or by interleukin-15. Finally, our findings reveal that CREM exerts its regulatory functions through epigenetic reprogramming of CAR-NK cells. Our results provide support for CREM as a therapeutic target to enhance the antitumour efficacy of CAR-NK cells."
Article snippet: CREM (Creative Diagnostics, CABT-B10032, 1:2,000)
Figure 1. CREM upregulation is mediated through the PKA–pCREB axis.